Search results for: NICE
Filter search results
Compared to what? How the choice of comparator affects new medicines
14 September 2026
…for. Some HTA agencies, such as NICE, may accept an ‘off-label’ medicine, in which case, the comparator’s cost can vary considerably depending on its exclusivity status, producing effects on access…
OHE responds to the NHS Productivity Commission report
22 September 2026
…as the Cancer Drugs Fund and Innovative Medicines Fund. A complete picture of NHS productivity needs to account for the health system as a whole, including NICE, regulators, and industry.”…
Report calls for investment in medical simulation to improve health and growth
21 October 2026
…for Health and Care Excellence (NICE) and the Health Research Authority (HRA). A further 85 national and international organisations from academia, industry, and regulation are taking part. UK CEiRSI’s aim…
OHE at ISPOR Europe 2026
8 November 2026, 12:00am
…13:45-14:45 Issue Panel Shaping the Global Research and Policy Agenda in HEOR in the Next Decade: A Value in Health Regional Issues Forum Lotte Steuten (panellist) 15:15-16:15 Forum NICE Optimised…
Workshop on HTA and Regulatory Review
13 May 2010
Tensions between broad access to new medical technologies and efforts to contain health care costs are perennial. In recent years, this has become evident in the uncomfortable discontinuities that can…
Australia’s Publicly Funded Vaccines Market
1 December 2010
The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the Federal German Ministry of…
Overview of the Economics of the Market for Medicines in the UK
29 March 2012
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2012 activities, he recently gave a comprehensive lecture on…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
The OHE has been very active in conceptualising approaches incorporating a broader assessment of the elements of value (often called “value based pricing” or “VBP”), as its publications to date…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…